To investigate whether PRDX1 promotes CRC progression by regulating tumor immune microenvironment in vivo, we treated WT and PRDX1‐KO (knockout) mice with AOM/DSS and found that the number of colitis‐associated colonic adenocarcinomas was significantly reduced in PRDX1‐KO mice compared to WT mice as described previously [11]. This evidence concerns the gene PRDX1 and colitis.